vs
BIOMERICA INC（BMRA）与奎斯特诊断（IMDX）财务数据对比。点击上方公司名可切换其他公司
BIOMERICA INC的季度营收约是奎斯特诊断的1.1倍（$1.2M vs $1.1M）。BIOMERICA INC净利率更高（-109.1% vs -2015.4%，领先1906.3%）。奎斯特诊断同比增速更快（-23.4% vs -26.0%）。过去两年奎斯特诊断的营收复合增速更高（154.4% vs 9.1%）
Biomerica Inc.是一家全球性医疗技术企业，研发、生产及销售诊断检测试剂盒与相关医疗产品，产品线覆盖胃肠疾病、传染病、食物不耐受检测及即时检测解决方案，服务全球多地的临床实验室、医疗机构及零售医疗客户。
奎斯特诊断公司是一家美国临床检验企业，跻身财富500强，业务覆盖美国本土，以及波多黎各、墨西哥、巴西等地区，同时与全球多家医院和诊所保持合作关系，是行业内颇具影响力的医疗诊断服务提供商。
BMRA vs IMDX — 直观对比
营收规模更大
BMRA
是对方的1.1倍
$1.1M
营收增速更快
IMDX
高出2.7%
-26.0%
净利率更高
BMRA
高出1906.3%
-2015.4%
两年增速更快
IMDX
近两年复合增速
9.1%
损益表 — Q2 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2M | $1.1M |
| 净利润 | $-1.3M | $-23.0M |
| 毛利率 | 4.2% | 42.5% |
| 营业利润率 | -113.5% | -2057.5% |
| 净利率 | -109.1% | -2015.4% |
| 营收同比 | -26.0% | -23.4% |
| 净利润同比 | -38.9% | 31.5% |
| 每股收益（稀释后） | $-0.45 | $-0.75 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BMRAIMDX
| Q4 25 | $1.2M | $1.1M | ||
| Q3 25 | $1.4M | $260.0K | ||
| Q2 25 | $749.0K | $518.0K | ||
| Q1 25 | $1.1M | $2.1M | ||
| Q4 24 | $1.6M | $1.5M | ||
| Q3 24 | $1.8M | $115.0K | ||
| Q2 24 | $1.1M | $104.0K | ||
| Q1 24 | $1.0M | $176.0K |
净利润BMRAIMDX
| Q4 25 | $-1.3M | $-23.0M | ||
| Q3 25 | $2.0K | $-10.9M | ||
| Q2 25 | $-1.5M | $-9.7M | ||
| Q1 25 | $-1.2M | $-6.7M | ||
| Q4 24 | $-950.0K | $-33.5M | ||
| Q3 24 | $-1.3M | $-13.5M | ||
| Q2 24 | $-1.4M | $-4.5M | ||
| Q1 24 | $-1.9M | $-9.1M |
毛利率BMRAIMDX
| Q4 25 | 4.2% | 42.5% | ||
| Q3 25 | 30.7% | 53.5% | ||
| Q2 25 | -33.0% | 67.6% | ||
| Q1 25 | 1.7% | 62.0% | ||
| Q4 24 | 26.7% | 40.0% | ||
| Q3 24 | 16.0% | 43.5% | ||
| Q2 24 | 2.1% | 48.1% | ||
| Q1 24 | -14.7% | 25.6% |
营业利润率BMRAIMDX
| Q4 25 | -113.5% | -2057.5% | ||
| Q3 25 | -81.0% | -4249.2% | ||
| Q2 25 | -209.1% | -1900.0% | ||
| Q1 25 | -108.1% | -318.0% | ||
| Q4 24 | -60.7% | -2262.9% | ||
| Q3 24 | -75.7% | -11752.2% | ||
| Q2 24 | -136.6% | -4453.8% | ||
| Q1 24 | -196.7% | -5265.3% |
净利率BMRAIMDX
| Q4 25 | -109.1% | -2015.4% | ||
| Q3 25 | 0.1% | -4174.6% | ||
| Q2 25 | -206.1% | -1880.7% | ||
| Q1 25 | -103.9% | -312.0% | ||
| Q4 24 | -58.1% | -2255.1% | ||
| Q3 24 | -72.8% | -11733.0% | ||
| Q2 24 | -127.1% | -4355.8% | ||
| Q1 24 | -188.6% | -5186.9% |
每股收益（稀释后）BMRAIMDX
| Q4 25 | $-0.45 | $-0.75 | ||
| Q3 25 | $0.00 | $-0.34 | ||
| Q2 25 | $-0.99 | $-0.30 | ||
| Q1 25 | $-0.48 | $-0.26 | ||
| Q4 24 | $-0.06 | $-2.19 | ||
| Q3 24 | $-0.63 | $-0.98 | ||
| Q2 24 | $-2.57 | $-0.36 | ||
| Q1 24 | $-0.11 | $-1.13 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.5M | $11.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $4.4M | $-31.5M |
| 总资产 | $6.0M | $25.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BMRAIMDX
| Q4 25 | $2.5M | $11.6M | ||
| Q3 25 | $3.1M | $18.7M | ||
| Q2 25 | $3.1M | $24.3M | ||
| Q1 25 | $3.1M | $31.0M | ||
| Q4 24 | $2.4M | $8.6M | ||
| Q3 24 | $2.8M | $3.4M | ||
| Q2 24 | $4.2M | $9.3M | ||
| Q1 24 | $5.3M | $5.6M |
股东权益BMRAIMDX
| Q4 25 | $4.4M | $-31.5M | ||
| Q3 25 | $5.2M | $-9.2M | ||
| Q2 25 | $4.1M | $1.1M | ||
| Q1 25 | $5.5M | $10.2M | ||
| Q4 24 | $5.1M | $-12.3M | ||
| Q3 24 | $5.3M | $9.7M | ||
| Q2 24 | $6.6M | $22.7M | ||
| Q1 24 | $7.8M | $11.6M |
总资产BMRAIMDX
| Q4 25 | $6.0M | $25.8M | ||
| Q3 25 | $6.9M | $43.9M | ||
| Q2 25 | $5.9M | $50.5M | ||
| Q1 25 | $7.4M | $60.4M | ||
| Q4 24 | $7.3M | $35.1M | ||
| Q3 24 | $7.9M | $70.2M | ||
| Q2 24 | $9.3M | $74.7M | ||
| Q1 24 | $10.3M | $71.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-991.0K | $-5.5M |
| 自由现金流经营现金流 - 资本支出 | — | $-7.0M |
| 自由现金流率自由现金流/营收 | — | -616.7% |
| 资本支出强度资本支出/营收 | — | 129.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-25.4M |
8季度趋势，按日历期对齐
经营现金流BMRAIMDX
| Q4 25 | $-991.0K | $-5.5M | ||
| Q3 25 | $-268.0K | $-4.5M | ||
| Q2 25 | $-661.0K | $-6.3M | ||
| Q1 25 | $-1.0M | $-5.9M | ||
| Q4 24 | $-791.0K | $-5.4M | ||
| Q3 24 | $-1.3M | $-5.5M | ||
| Q2 24 | $-1.0M | $-6.0M | ||
| Q1 24 | $-1.8M | $-3.8M |
自由现金流BMRAIMDX
| Q4 25 | — | $-7.0M | ||
| Q3 25 | — | $-5.6M | ||
| Q2 25 | — | $-6.6M | ||
| Q1 25 | — | $-6.2M | ||
| Q4 24 | — | $-5.6M | ||
| Q3 24 | — | $-5.6M | ||
| Q2 24 | $-1.1M | $-6.2M | ||
| Q1 24 | — | $-3.9M |
自由现金流率BMRAIMDX
| Q4 25 | — | -616.7% | ||
| Q3 25 | — | -2135.4% | ||
| Q2 25 | — | -1279.5% | ||
| Q1 25 | — | -288.4% | ||
| Q4 24 | — | -374.5% | ||
| Q3 24 | — | -4884.3% | ||
| Q2 24 | -95.5% | -5931.7% | ||
| Q1 24 | — | -2189.8% |
资本支出强度BMRAIMDX
| Q4 25 | — | 129.9% | ||
| Q3 25 | — | 403.8% | ||
| Q2 25 | — | 67.4% | ||
| Q1 25 | — | 14.4% | ||
| Q4 24 | — | 14.4% | ||
| Q3 24 | — | 75.7% | ||
| Q2 24 | 2.1% | 183.7% | ||
| Q1 24 | 0.0% | 13.6% |
现金转化率BMRAIMDX
| Q4 25 | — | — | ||
| Q3 25 | -134.00× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
